Meningococcal Disease, 2016
Five Neisseria meningitidis (NM) invasive disease cases (0.09 per 100,000 population) were reported in 2016; 7 cases were reported in 2015. Two were serogroup C, 2 were serogroup Y, and 1 case was serogroup B. All cases were sporadic.
Cases ranged in age from 12 years to 89 years. Three of the 5 occurred in the metropolitan area, while in 2015, 5 of the 7 cases occurred in Greater Minnesota area. Two cases had meningitis, 2 had bacteremia without another focus of infection, and 1 had pneumonia. There were no deaths.
One case-isolate demonstrated intermediate resistance to both ampicillin and penicillin. No isolate had ciprofloxacin resistance. Incidence of invasive NM was fairly stable at about 0.30 cases per 100,000 persons since 2005 (with the exception of 2008 when incidence increased to 0.57 cases per 100,000 persons); however, invasive NM has decreased since 2011. Quadrivalent MenACWY is recommended at 11-12 years with a necessary booster at age 16. Vaccination rates for at least 1 dose among 13-17 year old Minnesota adolescents have increased from 39% percent in 2008 to 84% percent in 2015 (National Immunization Survey Teen, CDC).
In Minnesota, from 2011-2016 the proportion of invasive NM cases that were serogroup B was 53% compared to the prior 6 years (2005-2010) when 36% of cases were serogroup B. Two menB vaccines are available; clinicians should vaccinate patients 10 years of age and older with specific risk factors, and discuss MenB vaccine with patients who are 16-23 years old.
- For up to date information see>> Meningococcal Disease
- Full issue>> Annual Summary of Communicable Diseases Reported to the Minnesota Department of Health, 2016